Thermo Fisher Scientific (TMO) Getting Somewhat Favorable News Coverage, Report Shows
News articles about Thermo Fisher Scientific (NYSE:TMO) have trended somewhat positive on Friday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Thermo Fisher Scientific earned a news impact score of 0.23 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 46.3617561549391 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Thermo Fisher Scientific (TMO) Upgraded to Buy from a Hold – Investorplace.com (investorplace.com)
- An Intrinsic Value Calculation For Thermo Fisher Scientific Inc (TMO) Shows Investors Are Overpaying (finance.yahoo.com)
- Thermo Fisher Scientific Inc. (NYSE: TMO) – Glistening Stock’s Review – Alpha Beta Stock (alphabetastock.com)
- Thermo Fisher Scientific Recommends Shareholders Reject Mini-Tender Offer by TRC Capital Corporation (finance.yahoo.com)
Thermo Fisher Scientific (TMO) traded up $0.76 on Friday, reaching $193.51. The company had a trading volume of 374,481 shares, compared to its average volume of 1,543,035. Thermo Fisher Scientific has a 12-month low of $139.07 and a 12-month high of $201.20. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. The firm has a market cap of $77,291.86, a price-to-earnings ratio of 21.18, a P/E/G ratio of 1.76 and a beta of 1.08.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. During the same period in the previous year, the company earned $2.03 EPS. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. research analysts expect that Thermo Fisher Scientific will post 9.36 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be issued a $0.15 dividend. The ex-dividend date is Thursday, December 14th. This represents a $0.60 annualized dividend and a yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.19%.
TMO has been the subject of several research reports. Cowen Inc reiterated an “outperform” rating and set a $220.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. Leerink Swann lifted their price target on Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a report on Monday, October 9th. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Goldman Sachs Group, Inc. (The) initiated coverage on Thermo Fisher Scientific in a report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target for the company. Finally, Deutsche Bank AG set a $226.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Thursday, October 26th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $205.71.
In related news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total value of $9,419,500.00. Following the completion of the sale, the chief executive officer now directly owns 252,577 shares in the company, valued at approximately $47,582,981.03. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director C Martin Harris sold 360 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total value of $65,149.20. Following the completion of the transaction, the director now directly owns 5,312 shares in the company, valued at $961,312.64. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 60,420 shares of company stock valued at $11,308,477. Corporate insiders own 0.49% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.